Methadone: applied pharmacology and use as adjunctive treatment in chronic pain

R Brown, C Kraus, M Fleming, S Reddy

This article reviews the unique pharmacological properties of methadone and outlines its appropriate clinical application, with focus upon its use in the treatment of chronic pain. Although methadone is most widely known for its use in the treatment of opioid dependence, methadone also provides effective analgesia. Patients who experience inadequate pain relief or intolerable side effects with other opioids or who suffer from neuropathic pain may benefit from a transition to methadone as their analgesic agent. Adverse effects, particularly respiratory depression and death, make a fundamental knowledge of methadone’s pharmacological properties essential to the provider considering methadone as analgesic therapy for a patient with chronic pain.

Methadone is a synthetic opioid medication best known for its use in the treatment of opioid dependence. Methadone is also an effective analgesic agent, potentially with increased efficacy in the setting of neuropathic pain. Patients experiencing inadequate analgesia or adverse effects while on other opioids may also benefit from a transition to methadone. Additionally, unique pharmacological properties make methadone a useful addition to the care provider’s arsenal of prescription analgesic agents.

Methadone’s excellent oral bioavailability and mucosal absorption, effectiveness as an analgesic agent, low cost, long half life, and availability in oral, parenteral, and suppository forms make it an excellent alternative for the treatment of both cancer and non-cancer pain. Medication interactions and the potential for serious adverse effects (particularly central apnoea and death, which have received recent attention in the popular press) make an understanding of methadone’s pharmacological profile essential to the prescribing provider.

Many individuals participating in methadone maintenance treatment for opioid dependence seek medical care in the community outside of their addiction treatment facility. An understanding of potential adverse effects and medication interactions is important when caring for this population as well, so that the provider can avert untoward events resulting from medication interactions.

In this article, we discuss the pharmacology of methadone and briefly comment upon its use in the treatment of opioid dependence and withdrawal. We then focus upon an approach to the prescription of methadone for the treatment of chronic pain conditions. Finally, we discuss the adverse effects of and potential drug interactions with methadone which may occur with usual clinical use.

PHARMACOLOGY

Methadone occurs in R-enantimoric and S-enantimoric forms, with essentially all of its activity due to activity of R-methadone. Methadone exerts its activity through binding to and activating μ opioid receptors centrally and in the periphery. This activity produces the effects common to all μ opioid agonists: analgesia, euphoria, constipation, sedation, respiratory depression, nausea, and miosis. Additionally, methadone antagonises N-methyl-D-aspartate receptors, which may increase its effectiveness in the treatment of neuropathic pain compared with other opioids.

Pharmacokinetics

Methadone is a fat soluble drug which is rapidly absorbed after oral administration. Time to peak concentration, however, varies from one to five hours. Methadone induced slowing of gastric emptying may account for longer time to peak concentration in chronic users. Oral bioavailability of tablets is approximately 60%–70%, but wide variation among patients exists. The analgesic effect of a dose begins within 30 to 60 minutes after administration and generally lasts for four to six hours.

Methadone is highly bound to plasma proteins. In particular, ζ1-acid glycoprotein is important, because disease states, like cancer, may induce a rise in the concentration of this protein and, as a result, affect the concentration of free methadone. Certain drugs may influence ζ1-acid glycoprotein concentrations and, in turn, methadone concentrations. Methadone may be displaced from plasma proteins by drugs like propranolol, certain phenothiazines, and imipramine. Other drugs may decrease plasma protein and, theoretically, increase free methadone levels. Examples of such drugs are carmustine and mechlorethamine. Finally, drugs may also selectively compete for protein binding sites, resulting in situations where their own free levels might increase. The tricylic antidepressants, progesterone, and lidocaïne are a few examples. Although animal data suggest that dose adjustments based on protein binding may be necessary, there are no data in humans to suggest these interactions are clinically significant.
Methadone is also widely distributed to tissue, and, with continuous use, tissue levels may exceed levels in plasma. This extensive protein and tissue binding is responsible for the long plasma half life of the drug, particularly with continuous use. Metabolism of methadone to inactive forms is the principle means of elimination. Less than 10% of an oral dose is extracted by the liver during first pass. The drug is metabolized both by the liver and by intestinal CYP 3A4 and, to a lesser extent, by CYP 2D6. Some of the variability of enzyme activity in different people likely accounts for the large differences in clearance and half life of methadone seen within a population. For example, due to a polymorph of CYP 2D6, a subset of the white population, less than 10%, are considered to be poor metabolisers of methadone. Estimates of methadone half life vary from 15 to 55 hours. In addition to metabolic inactivation, parent drug and metabolites are also eliminated in the faeces and urine.

Age does not appear to have a large influence on clearance and generally no change in dose is required for persons over age 65 years. For patients with impaired renal function, methadone clearance via faeces will increase and no dose adjustment is necessary. For patients with end stage renal disease, some experts suggest a 50% reduction in methadone dosing. Because methadone is highly protein bound, little is expected to be removed from the plasma with dialysis. Patients with chronic, stable liver diseases may be able to tolerate usual methadone maintenance doses. For patients with acute hepatitis and elevated liver enzymes, higher doses of methadone may be required.

No relationship has been established between plasma concentration and analgesic effect. For the treatment of chronic pain, treatment should be titrated to clinical effect rather than a drug level.

**CLINICAL APPLICATIONS**

**Methadone for opioid dependence**

Since the enactment of the Narcotic Addicts Treatment Act in 1973, methadone prescription in the United States for opioid dependence or opioid withdrawal has been (and continues to be) legal only in the setting of a federally licensed methadone maintenance facility. Resources for the care of health issues unrelated to substance abuse are often limited in these facilities. Methadone maintained individuals, therefore, frequently seek medical care from community providers. Over 150,000 opioid dependent individuals are enrolled in methadone treatment centres in the United States. The United States Office of National Drug Control Policy estimates that these services reach one in 10 to one in eight actively opioid dependent individuals in the United States.

Methadone maintenance treatment has been shown to decrease use of heroin and other drugs; reduce the acquisition and transmission of HIV, hepatitis B, and hepatitis C; reduce criminal behaviour; and has been shown to be a cost effective treatment for opioid dependence. Most of the benefits of methadone maintenance have been shown to be related to methadone dose and to duration of treatment.

**Methadone for chronic pain**

Federal and state regulations restricting the use of methadone in the setting of opioid dependence and withdrawal to specially licensed facilities do not apply to the prescription of methadone for chronic pain. Therefore, the care provider may consider the use of methadone as an analgesic agent for the treatment of chronic pain.

In addition to being effective treatment for opioid dependence, methadone provides effective analgesia with several unique properties. Patients experiencing adverse effects (constipation, euphoria, nausea/vomiting) or inadequate analgesia with other prescribed opioids may benefit from a transition to methadone. Additionally, methadone often provides analgesia superior to other opioids in the setting of neuropathic pain syndromes. Furthermore, a reduced level of tolerance to analgesic effects and less constipation has been reported for methadone as opposed to other opioids.

Given the short duration of analgesia (4–6 hours) relative to methadone’s half life, the use of methadone as an analgesic agent requires a more frequent dosing regimen than the daily dosing used for the treatment of opioid dependence. Usual analgesic treatment regimens with methadone require dosing every eight to 12 hours. The long half life of methadone in the setting of more frequent dosing creates the potential for drug accumulation and adverse effects. Many protocols for a transition from methadone from other opioid analgesics have been put forward in the literature. These methods are of two basic types: (1) a rapid transition in which the previously prescribed opioid is completely discontinued with institution of methadone analgesic therapy, and (2) a slow transition in which the previously prescribed opioid is tapered in conjunction with titration of methadone dosing. Equianalgesic doses of the most commonly prescribed opioids are provided in table 1.

---

**Table 1. Opiate milligram equivalents**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Equianalgesic doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Codeine</td>
<td>180–200 mg</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>25 mg transdermal</td>
</tr>
<tr>
<td>Hydrocodone</td>
<td>30 mg</td>
</tr>
<tr>
<td>Morphine</td>
<td>30–60 mg oral</td>
</tr>
<tr>
<td>Oxycodone</td>
<td>30 mg</td>
</tr>
</tbody>
</table>

*Methadone conversion is not included due to varying conversion ratios at varying prior doses of other opioids. See boxes 1 and 2 for appropriate conversion to methadone based upon morphine milligram equivalents.*
is not recommended routinely for all patients receiving methadone maintenance.¹¹ No relationship has been established between plasma concentration and analgesic effect.⁹ For the treatment of chronic pain, therefore, treatment should be titrated to clinical effect rather than a drug level.³

**CESSATION/TAPER OF METHADONE**

Should cessation of methadone treatment be indicated, gradual tapering will minimise withdrawal symptoms. The taper generally should not exceed 1 mg/day.³¹ A 5 mg/week taper is convenient given methadone’s availability in 5 mg and 10 mg tablet forms.

Aching muscles and joints, insomnia, nausea, and mood changes may indicate opioid withdrawal.³² If the patient begins to experience opioid withdrawal effects, symptomatic treatments on an as-needed basis may assist in the management of a continued taper if necessary. Clonidine or a β-blocker may alleviate sympathomimetic symptoms (tachycardia, lacrimation, stuffy nose, sweats). These medications may not be needed for all patients, and adjustments may indicate opioid withdrawal.³²

**Table 2 Drug interactions associated with enhanced methadone effects**

<table>
<thead>
<tr>
<th>Antibiotics</th>
<th>Pharmacokinetic effects</th>
<th>Clinical effects</th>
<th>Type of evidence</th>
<th>Possible mechanism</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ciprofloxacin</td>
<td>35% ↑ AUC, 27% ↑ peak, 48% ↓ trough, 24% ↓ clearance methadone</td>
<td>Sedation/respiratory depression/confusion</td>
<td>Single case report; ciprofloxacin reintroduced with same outcome</td>
<td>Inhibition of CYP1A2 and/or CYP3A4</td>
<td>39</td>
</tr>
<tr>
<td>Fluconazole</td>
<td>35% ↑ AUC, 27% ↑ peak, 48% ↓ trough, 24% ↓ clearance methadone</td>
<td>No signs/symptoms of methadone overdose reported</td>
<td>Randomised, double blind, placebo controlled trial; 13 participants received fluconazole 200 mg/day</td>
<td>Inhibition of CYP3A4, possibly others</td>
<td>38</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>Fluoxetine</td>
<td>Some patients had moderate ↑ plasma level, but this was less marked than with fluvoxamine in the two patients</td>
<td>None reported</td>
<td>Nine case reports of serum levels of methadone after addition of fluoxetine; two participants had also use fluvoxamine previously</td>
<td>Inhibition of CYP2D6</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>↑ serum methadone level</td>
<td>Hypoxemia, hypercapnia</td>
<td>Single case</td>
<td>Inhibition of one of several enzymes: CYP3A4, CYP1A2, CYP2C9, CYP2C19</td>
<td>41</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>↑ R-methadone plasma levels in eight CYP2D6 extensive metabolisers but not in poor metabolisers</td>
<td>No side effects reported by patients and no signs of intoxication were noted</td>
<td>Prospective administration of paroxetine in 10 methadone-using patients (two poor metabolisers, eight extensive metabolisers)</td>
<td>Inhibition of CYP2D6; also possibly CYP1A2, CYP2C9, CYP2C19, and CYP3A4</td>
<td>43</td>
</tr>
<tr>
<td>Sertraline</td>
<td>↑ methadone plasma level 26% with addition of sertraline</td>
<td>No significant difference in side effects between groups of sertraline</td>
<td>Prospective, 12 week, randomised, placebo controlled trial; 12 patients received up to sertraline 200 mg/day</td>
<td>Inhibition of several isoenzymes (CYP2D6, CYP3A4, CYP1A2, CYP2C19)</td>
<td>44</td>
</tr>
</tbody>
</table>

Adapted with permission from Eap CB, Buclin T, Baumann P. Interindividual variability of clinical pharmacokinetics of methadone. Clin Pharmacokinet 2002; 41:1153-93. AUC, area under the curve.
methadone regimen, will obviate the unnecessary laboratory work. Familiarity with the side effect profile of methadone will assist in the appropriate titration of a medication side effects, and may assist the practitioner in the management of these side effects.

Methadone acts upon central opioid receptors, as do the other opioid drugs. This action may reduce hypercapnoeic symptoms and hypoxic ventilatory drives resulting in respiratory depression. The most severe potential consequence of this effect is central apnoea. Many cases of mortality due to this effect have been reported. In most situations, medication interactions were missed, medical risk factors ignored, or doses increased too quickly. Methadone toxicity can also result from inadequately spaced dosage regimens (dosing more frequently than every eight hours) due to the drug’s long half life and consequent drug accumulation. Careful

### SIDE EFFECTS OF METHADONE

Familiarity with the side effect profile of methadone will assist the practitioner in the appropriate titration of a methadone regimen, will obviate the unnecessary laboratory investigation of signs and symptoms known to be common to methadone.

#### Table 3 Drug interactions associated with diminished methadone effects

<table>
<thead>
<tr>
<th>Antibiotics</th>
<th>Pharmacokinetic effects</th>
<th>Clinical effects</th>
<th>Type of evidence</th>
<th>Possible mechanism</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fusidic acid</td>
<td>Total clearance antipyrine ↑ in group using fusidic acid × 28 days</td>
<td>No side effects were reported by patients; some patients in 28 day group developed signs of underdosage</td>
<td>Randomised, prospective trial, placebo controlled. Ten patients received fusidic acid 500 mg/day × 14 days; 10 patients with same dose × 28 days; 10 patients received no additional meds. Antipyrine clearance used to assess effect on CYP450 system</td>
<td>Induction of CYP450 enzymes</td>
<td>46</td>
</tr>
<tr>
<td>Rifampin</td>
<td>↓ methadone plasma level</td>
<td>Methadone withdrawal symptoms</td>
<td>Case</td>
<td>Induction of CYP3A4</td>
<td>12, 47</td>
</tr>
</tbody>
</table>

#### Antivirals/non-nucleoside reverse transcriptase inhibitors

| Efavirenz | Marked ↓ maximum plasma methadone concentration, ↓ AUC | Nine patients described symptoms of methadone withdrawal | Prospective trial of 11 patients using methadone and beginning therapy with efavirenz | Induction of CYP3A4 | 48 |
| Nevirapine | Three of seven records had a documented decrease in methadone trough level or subtherapeutic level | Two of seven records had evidence of opiate withdrawal | Retrospective chart review of 800 records of HIV-infected patients | Induction of CYP3A4 | 49 |

#### Antivirals/nucleoside reverse transcriptase inhibitors

| Abacavir | Administration of both abacavir and amprenavir associated with median 65% decrease in methadone concentration | Two patients of the five reported symptoms consistent with withdrawal | Prospective administration of abacavir and amprenavir to five patients using methadone. Abacavir not expected to induce CYP3A4 activity; the protease inhibitor, amprenavir, is a known inducer of CYP3A4 and more likely the cause of ↓ methadone concentration | | 50 |

#### Antivirals/protease inhibitors

| Amprenavir (see abacavir statement) | | | | | |
| Nelfinavir | | | | | |
| Ritonavir/ saquinavir | 40% ↓ AUC in S-methadone and 32% ↓ AUC in R-methadone | No evidence of withdrawal reported | Single case report nelfinavir 750 mg three times a day added to drug regimen. Prospective pharmacokinetic study of 12 patients using methadone who began 400 mg ritonavir and 400 mg saquinavir twice daily | Induction of CYP3A4, possible induction of P-glycoprotein | 52 |

Adapted with permission from Eap CB, Buclin T, Baumann P. Interindividual variability of clinical pharmacokinetics of methadone. Clin Pharmacokinet 2002;41:1153–93. AUC, area under the curve.
Dose titration, a thorough history for medical risk factors, and cognisance of medication interactions should avert this potentially catastrophic effect.

Due to central opioid receptor activation, somnolence is quite common during the first weeks of treatment before tolerance to this drug effect is gained. Methadone may also interfere with rapid eye movement sleep and sleep stages 3 and 4. When these changes persist during chronic treatment, insomnia may occur. Patients experiencing this side effect have lower sleep efficiency, less rapid eye movement, and less slow wave sleep accompanied by sleep disordered breathing. Additionally they spend more time in sleep stage 2.18

Methadone maintenance patients may also experience subjective cognitive slowing. Objective, controlled data on this phenomenon are scarce. Tolerance would be expected to this side effect as has been demonstrated with the chronic use of other opioid medications. A European study examining the cognitive effects of chronic methadone therapy concluded that methadone treatment was not, in itself, predictive of impairment in cognitive psychomotor skills; inferior performance on tests was more strongly related to sociodemographic factors. A second study demonstrated that psychophysical performances and driving aptitude are not significantly related to methadone dose.19

Weight gain is a commonly reported side effect among patients on methadone maintenance. The precise aetiology is unclear but may involve appetite increase and/or non-cardiogenic peripheral oedema. Previous studies have indicated an onset of weight gain three to six months after initiation of methadone maintenance treatment or after a sharp dosage increase.30 31 Sexual dysfunction is also a common complaint of individuals on chronic methadone. In men, orgasm dysfunction and a decrease in libido are the most common concerns. Spermatic dysmotility has also been described.33 34 Whether or not fertility is adversely affected has yet to be firmly established. Several studies that indicate subnormal levels of plasma testosterone in men maintained on methadone may account for these side effects, though a dose effect relationship has yet to be discovered.35 36 Women may experience dysfunction of libido as well as oligomenorrhoea or amenorrhoea.37 The aetiology of and potential treatments for these effects are unclear.

Up to 65% of patients report constipation as a direct effect of methadone.38 Tolerance to this peripheral opioid effect may not develop, often necessitating a scheduled bowel regimen during treatment with methadone.41

Drugs which induce enzyme systems responsible for methadone metabolism may result in lowering of methadone levels. It is thought that chronic abuse of alcohol may increase liver enzymes and reduce methadone levels.39 40 Seizure medications like phenytoin, phenobarbital, and carbamazepine are classic examples of CYP3A4 enzyme inducers that may lower methadone concentrations.41 Of the antibiotics, rifampin has been shown to interfere with methadone. Of the antiviral medications used for the treatment of HIV, the non-nucleoside reverse transcriptase inhibitors increase the metabolism of methadone. Drug interactions resulting in lowered methadone concentrations can be found in table 3.37 38 41 42

Methadone levels may be affected by competition for enzyme metabolism. For example, some feel that binge drinking of alcohol may prevent appropriate metabolism of methadone, temporarily increasing concentrations.43 One example of preferential metabolism of methadone is its interaction with zidovudine, where increased zidovudine levels have been described.44 On the other hand, methadone appears to decrease the concentration of stavudine and didanosine by apparently decreasing their absorption.45 Finally, both alcohol and benzodiazepines have been associated with increased risk for respiratory depression in patients using opioids.14

CONCLUSION

In summary, methadone has important therapeutic applications beyond methadone maintenance for opioid dependence. It is a viable choice for patients with neuropathic pain, for pain resistant to treatment with other opioid analgesics, and for situations where dose limiting side effects occur from other opioid agents. Practitioners who prescribe methadone need to be familiar with its unique pharmacokinetic profile, side effects, and potential drug interactions to ensure safe, effective use of this agent.

Authors’ affiliations
R Brown, University of Wisconsin Department of Family Medicine and Department of Population Health Sciences, and Madison Health Services Methadone Treatment Facility, Madison, Wisconsin, USA
C Kraus, University of Wisconsin Department of Pharmacy, Madison, Wisconsin, USA
M Fleming, University of Wisconsin Department of Family Medicine, Madison, Wisconsin, USA
S Reddy, University of Wisconsin Medical School, Madison, Wisconsin, USA

REFERENCES

80% in vitro, many of these agents do not exhibit the same degree of inhibition in vivo.43 A summary of medications associated with increased concentrations of methadone are found in table 2.44 45

Dose titration, a thorough history for medical risk factors, and cognisance of medication interactions should avert this potentially catastrophic effect.